Search results for "hole"

showing 10 items of 2900 documents

Personalized intraoperative positive end-expiratory pressure: a further step in protective ventilation

2017

business.industryRespiration030204 cardiovascular system & hematologyPositive-Pressure Respiration03 medical and health sciencesProtective ventilation0302 clinical medicineAnesthesiology and Pain MedicineText miningCholecystectomy Laparoscopic030202 anesthesiologyAnesthesiaMedicinebusinessLungPositive end-expiratory pressureMinerva Anestesiologica
researchProduct

Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mous…

2013

The t(8;21) chromosomal translocation activates aberrant expression of the AML1-ETO (AE) fusion protein and is commonly associated with core binding factor acute myeloid leukaemia (CBF AML). Combining a conditional mouse model that closely resembles the slow evolution and the mosaic AE expression pattern of human t(8;21) CBF AML with global transcriptome sequencing, we find that disease progression was characterized by two principal pathogenic mechanisms. Initially, AE expression modified the lineage potential of haematopoietic stem cells (HSCs), resulting in the selective expansion of the myeloid compartment at the expense of normal erythro- and lymphopoiesis. This lineage skewing was foll…

cancer stem cellsCancer stem cells; Core binding factor acute myeloid leukaemia; Preclinical mouse model; Therapy target validation; Whole transcriptome sequencingMyeloidtherapy target validationOncogene Proteins FusionCloseupsBiologyGranulocyte-Macrophage Progenitor CellsTranslocation Geneticwhole transcriptome sequencingImmunophenotypingMiceGranulocyte-Macrophage Progenitor CellsCancer stem cellhemic and lymphatic diseasesmedicineAML1-ETOAnimalsCell Lineageacute myeloid leukaemiaLymphopoiesisProgenitor cellt(8;21)Research Articlespreclinical mouse modelGeneticsRegulation of gene expressionAntibiotics AntineoplasticSequence Analysis RNAcore binding factor acute myeloid leukaemiainducible mouse-modelHematopoietic Stem CellsMice Inbred C57BLDisease Models AnimalLeukemia Myeloid AcuteHaematopoiesisPhenotypemedicine.anatomical_structureGene Expression RegulationDoxorubicinCancer researchNeoplastic Stem CellsMolecular MedicineStem cell
researchProduct

Effects of n-3 Polyunsaturated Fatty Acids (ω-3) Supplementation on Some Cardiovascular Risk Factors with a Ketogenic Mediterranean Diet

2015

Background: the ketogenic diet (KD) has become a widely used nutritional approach for weight loss. Some of the KD’s positive effects on metabolism and cardiovascular risk factors are similar to those seen after n-3 polyunsaturated fatty acids (ω-3) supplementation. We hypothesized that a ketogenic Mediterranean diet with phytoextracts combined with ω-3 supplementation may have increased positive effects on cardiovascular risk factors and inflammation. Methods: We analyzed 34 male overweight subjects

cardiovascular risk factorsBlood GlucoseMaleMediterranean dietinflammatory cytokinesmedicine.medical_treatmentN-3 polyunsaturated fatty acidPharmaceutical ScienceOverweightDiet Mediterraneanchemistry.chemical_compoundRisk FactorsWeight lossDrug DiscoveryInsulinlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)Adipositychemistry.chemical_classificationCardiovascular risk factors; Inflammatory cytokines; Ketogenic diet; N-3 polyunsaturated fatty acids; Omega-3; Weight loss; Drug Discovery3003 Pharmaceutical ScienceMiddle Agedn-3 polyunsaturated fatty acidsketogenic dietCardiovascular DiseasesCytokinesomega-3medicine.symptomDiet KetogenicPolyunsaturated fatty acidAdultmedicine.medical_specialtyInflammatory cytokineBiologyCardiovascular risk factorWeight loArticleInternal medicineFatty Acids Omega-3Weight LossmedicineHumansTriglyceridesAgedAdiponectinPlant ExtractsCholesterolDrug Discovery3003 Pharmaceutical Science<i>n</i>-3 polyunsaturated fatty acidsCholesterol LDLOverweightEndocrinologylcsh:Biology (General)chemistryDietary SupplementsUric acidKetogenic dietMarine Drugs
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (&lt;80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active &lt;30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea : data from t…

2020

Background and aim: Obstructive sleep apnea (OSA) is an independent risk factor for dyslipidemia. The current study examined the effects of positive airway pressure (PAP) treatment on lipid status in the European Sleep Apnea Database (ESADA). Methods: The prospective cohort study enrolled 1564 OSA subjects (74% male, mean age 54 ± 11y, body mass index (BMI) 32.7 ± 6.6 kg/m2 and apnea-hypopnea index (AHI) 40.3 ± 24.4 n/h) undergoing PAP therapy for at least three months (mean 377.6 ± 419.5 days). Baseline and follow-up total cholesterol (TC) from nine centers were analyzed. Repeated measures and logistic regression tests (adjusted for age, sex, weight changes, lipid lowering medication, PAP …

cardiovascular riskAdultMalemedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioPositive airway pressure03 medical and health sciences0302 clinical medicineInternal medicinePositive airway pressuremedicineCardiovascular risk Cholesterol Hypoxia Sleep apneaHumanspositive airway pressureProspective StudiesRisk factorProspective cohort studyHypoxiaAgedSleep Apnea ObstructiveFramingham Risk ScoreContinuous Positive Airway Pressurebusiness.industryhypoxiaSleep apneaSleep apneacholesterolGeneral MedicineMiddle Agedmedicine.diseasesleep apneaCardiovascular riskObstructive sleep apneaCardiovascular risk ; Cholesterol ; Hypoxia ; Positive airway pressure ; Sleep apnea.Cholesterol030228 respiratory systemPatient ComplianceFemaleHuman medicinebusinessBody mass index030217 neurology & neurosurgeryDyslipidemiaSleep medicine
researchProduct

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

2010

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in carotid int…

cardiovascular riskAortic valvemedicine.medical_specialtydyslipidaemiamedicine.drug_classezetimibe cardiovascular risk atherosclerosis dyslipidaemiachemistry.chemical_compoundEzetimibeInternal medicineClinical endpointMedicineCholesterol absorption inhibitorcardiovascular diseasesReview Paperbusiness.industryCholesterolnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStenosismedicine.anatomical_structureEndocrinologychemistrySimvastatinCardiologylipids (amino acids peptides and proteins)atherosclerosisbusinessezetimibeLipoproteinmedicine.drug
researchProduct

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.

2007

Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…

cardiovascular riskRiskStatinmedicine.drug_classHypercholesterolemiasubclassePharmacologyBioinformaticschemistry.chemical_compoundClofibric AcidEzetimibemedicineHumansPharmacology (medical)Cholesterol absorption inhibitorRosuvastatinRisk factorRosuvastatin CalciumNational Cholesterol Education ProgramSulfonamidessmall dense LDLfibrateCholesterolbusiness.industryAnticholesteremic AgentsstatinGeneral MedicineCholesterol LDLEzetimibeFluorobenzenesRosuvastatin CalciumPyrimidineschemistrydiabeteCardiovascular DiseasesAzetidineslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessrosuvastatinmedicine.drugAdvances in therapy
researchProduct

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid…

2022

Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum is…

cardiovascular riskSettore MED/09 - Medicina Internafamilial hypercholesterolemiaPCSK9 inhibitors cardiovascular risk cholesterol efflux capacity cholesterol loading capacity familial hypercholesterolemiaPCSK9 inhibitorsSettore BIO/14 - Farmacologiacholesterol loading capacityBiochemistry Genetics and Molecular Biology (miscellaneous)Molecular BiologyBiochemistrycholesterol efflux capacityPCSK9 inhibitors; cardiovascular risk; cholesterol efflux capacity; cholesterol loading capacity; familial hypercholesterolemiaFrontiers in molecular biosciences
researchProduct

European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subcl…

2011

Item does not contain fulltext Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

cardiovascular riskischemic-heart-diseaseHealth aging / healthy living [IGMD 5]coronary-artery-diseaseapolipoprotein-b metabolismcholesteryl ester transferAtherosclerosisstatementfamilial combined hyperlipidemialdlLipoproteins LDLvery-low-densitynuclear-magnetic-resonancec-reactive proteinRisk FactorsAnimalsHumansGenetic Predisposition to DiseaseLDL subclasses atherosclerosis cardiovascular risk statementsubclassesatherosclerosistype-2 diabetes-mellitusintima-media thickness
researchProduct

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia

2023

: Background Evidence suggests that LPA risk genotypes are a possible contributor to the clinical diagnosis of familial hypercholesterolemia (FH). This study aimed at determining the prevalence of LPA risk variants in adult individuals with FH enrolled in the Italian LIPIGEN (Lipid Transport Disorders Italian Genetic Network) study, with (FH/M+) or without (FH/M-) a causative genetic variant. Methods and Results An lp(a) [lipoprotein(a)] genetic score was calculated by summing the number risk-increasing alleles inherited at rs3798220 and rs10455872 variants. Overall, in the 4.6% of 1695 patients with clinically diagnosed FH, the phenotype was not explained by a monogenic or polygenic cause …

cardiovascular risklipoprotein(a).familial hypercholesterolemia
researchProduct